Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis

Arthritis and Rheumatism

Volumn 43, Issue 8, 2000, Pages 1698-1709

  Dreja, Hanna ^a   Annenkov, Alex ^a   Chernajovsky, Yuti ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; COMPLEMENT COMPONENT C3B RECEPTOR; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; FIBROBLAST; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPLEEN CELL;

ANIMALS; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COLLAGEN; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE PROGRESSION; DNA; FIBROBLASTS; GENE THERAPY; INJECTIONS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; RECEPTORS, COMPLEMENT; RETROVIRIDAE INFECTIONS;

EID: 0033892744     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200008)43:8<1698::AID-ANR5>3.0.CO;2-8     Document Type: Article

References (85)

1. The role of complement in the induction and regulation of immune responses
2. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement
3. Chemotactic response to human C3a and C5a anaphylatoxins
4. C3b covalently associated to tetanus toxin modulates TT processing and presentation by u937 cells
5. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes
6. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis
7. Complement receptor type 1 (CR1, CD35) is a receptor for C1q
8. C3, C4 and C5: The thioester site
9. The B lymphocyte as an immunotherapeutic target
10. Modulation of antigen processing and presentation by covalently linked complement C3b fragment
11. Suppression of the immune response by a soluble complement receptor of B lymphocytes
12. Primate erythrocyte-immune complex-clearing mechanism
13. Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees
14. CD21/CD35 in B cell activation
15. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane
16. Complement receptor is an inhibitor of the complement cascade
17. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor
18. The CD19 complex of B lymphocytes: Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex
19. Antibody response to a T-dependent antigen requires B cell expression of complement receptors
20. Complement activation and vascular injury in systemic lupus erythematosus
21. Breakdown products of C3 in human synovial fluids
22. Measurement of terminal complement complexes in rheumatoid arthritis
23. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid
24. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis
25. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein
26. The cartilage collagens: A review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease
27. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats
28. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: Effects of pre-treatment with cobra venom factor and anti-lymphocyte serum
29. Genetic control of susceptibility to collagen-induced arthritis in T cell receptor β-chain transgenic mice
30. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
31. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats
32. The effect of soluble complement receptor type 1 on hyperacute allograft rejection
33. Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection
34. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine
35. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury
36. Effect of soluble complement receptor type 1 on porphyrin-induced phototoxicity in guinea pigs
37. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis
38. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
39. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis
40. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis
41. Critical role of peripheral-blood phagocytes and the involvement of complement in tumor-necrosis-factor enhancement of passive collagen-arthritis
42. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59
43. Experimental murine acid aspiration injury is mediated by neutrophils and the alternative complement pathway
44. Microvascular effects on complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle
45. Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: A possible initiating role of B cells
46. Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance
47. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
48. High efficiency gene transfer into primary human tumor explants without cell selection
49. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity
50. Construction and use of a safe and efficient amphotropic packaging cell line
51. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter
52. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy
53. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
54. Mouse monoclonal antibodies to the human C3b receptor
55. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
56. PMA induces the ligand-independent internalization of CR1 on human neutrophils
57. Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1)
58. Activation of the alternate pathway of human complements by rabbit cells
59. Successful transfer of collagen-induced arthritis to severe combined immunodeficient (SCID) mice
60. Gene therapy of rheumatoid arthritis via cytokine regulation: Future perspectives
61. High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion
62. Bacterial lipopolysaccharide copurifies with plasmid DNA: Implications for animal models and human gene therapy
63. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities
64. Further differences in lymphokine synthesis between th1 and th2 clones revealed by RNA hybridisation, functionally monospecific bioassays, and monoclonal antibodies
65. Mapping epitopes for 20 monoclonal antibodies to CR1
66. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding
67. Designing CD4 immunoadhesins for AIDS therapy
68. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules
69. Influence of glycosylation on allelic and cell-specific Mr variation, receptor processing, and ligand binding of the human complement C3b/C4b receptor
70. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor
71. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor
72. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model
73. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis
74. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor
75. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA)
76. Leucocyte integrin and CR1 expression on peripheral blood leucocytes of patients with rheumatoid arthritis
77. Morphological evidence that activated polymorphs circulate in the peripheral blood of patients with rheumatoid arthritis
78. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis
79. Animal models for complement deficiencies
80. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes
81. Generation of three different fragments of bound C3 with purified factor I or serum
82. Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts
83. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor
84. Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors